ArticleApplied and environmental microbiology2006
Production of the lantibiotic salivaricin A and its variants by oral streptococci and use of a specific induction assay to detect their presence in human saliva.
Article in Applied and environmental microbiology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02407106 (Efficacy of Streptococcus Salivarius BLIS), which is not on this map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy of Streptococcus Salivarius BLIS (Bacteriocin-like Inhibitory Substance) K12 as Preventive Measure for Rheumatic Children.
Who cites it
54 citing papers in PubMed, 112 citations in OpenAlex.
- Environmental pH controls antimicrobial production by human probioticJournal of bacteriology · 2025Article
- TheJournal of bacteriology · 2025Article
- A gut-derivedmBio · 2025Article
- Beneficial changes in gut microbiota after phototherapy for neonatal hyperbilirubinemia.Biomedical reports · 2024Article
- Cell-free biosynthesis and engineering of ribosomally synthesized lanthipeptides.Nature communications · 2024Article
- Opposing genetic polymorphisms of two ABC transporters contribute to the variation of nukacin resistance inApplied and environmental microbiology · 2024Article
- A catalog of bacterial reference genomes from cultivated human oral bacteria.NPJ biofilms and microbiomes · 2023Article
- Beneficial modulation of human health in the oral cavity and beyond using bacteriocin-like inhibitory substance-producing streptococcal probiotics.Frontiers in microbiology · 2023Review
- Tonsillar Microbiome-Derived Lantibiotics Induce Structural Changes of IL-6 and IL-21 Receptors and Modulate Host Immunity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
- Mechanism of Action of Ribosomally Synthesized and Post-Translationally Modified Peptides.Chemical reviews · 2022Review
- Whole genome sequence analysis ofJournal of animal science and technology · 2022Article
- Bacteriocin ProducingMicroorganisms · 2022Article
- Oropharyngeal Probiotic ENT-K12 as an Effective Dietary Intervention for Children With Recurrent Respiratory Tract Infections During Cold Season.Frontiers in nutrition · 2022Article
- Bacteriocin Production by Beta-Hemolytic Streptococci.Pathogens (Basel, Switzerland) · 2021Review
- Toward understanding the signals of bacteriocin production by Streptococcus spp. and their importance in current applications.World journal of microbiology & biotechnology · 2021Review
- Targeting Microbiota: What Do We Know about It at Present?Medicina (Kaunas, Lithuania) · 2019Review
- Characterization of the Competitive Pneumocin Peptides ofFrontiers in cellular and infection microbiology · 2019Article
- Draft Genome Sequence of the Lantibiotic-Producing Strain Streptococcus salivarius HS0302.Microbiology resource announcements · 2019Article
- Covalent Structure and Bioactivity of the Type AII Lantibiotic Salivaricin A2.Applied and environmental microbiology · 2018Article
- Identification of a two-component Class IIb bacteriocin in Streptococcus pyogenes by recombinase-based in vivo expression technology.Scientific reports · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Salivaricin A (SalA), the first Streptococcus salivarius lantibiotic to be characterized, appears to be inhibitory to most Streptococcus pyogenes strains. A variant of the SalA structural gene (salA1) is present in more than 90% of S. pyogenes strains, but only strains of M serotype 4 and T pattern 4 produce the biologically active peptide. The present study identifies four additional variants (salA2 to salA5) of the SalA structural gene and demonstrates that each of the corresponding inhibitory peptides (SalA2 to SalA5) is produced in vitro. These variants appear to be similar to SalA and SalA1 in their inhibitory activity against Micrococcus luteus and in their ability to act as inducers of SalA production. It had previously been shown that S. pyogenes strain SF370 had a deletion (of approximately 2.5 kb) in the salM and salT genes of the salA1 locus. In the present study, several additional characteristic deletions within the salA1 loci were identified. S. pyogenes strains of the same M serotype all share the same salA1 locus structure. Since S. salivarius is a predominant member of the normal oral flora of healthy humans, strains producing anti-S. pyogenes lantibiotics, such as SalA, may have excellent potential for use as oral probiotics. In the present study, we have used a highly specific SalA induction system to directly detect the presence of SalA in the saliva of humans who either naturally harbor populations of SalA-producing S. salivarius or who have been colonized with the SalA2-producing probiotic S. salivarius K12.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.